Avidity Maturation of Antibodies After COVID-19 Vaccination
Author Information
Author(s): Emma Löfström, Anna Eringfält, Arne Kötz, Johan Tham, Johan Undén
Primary Institution: Lund University
Hypothesis
How does the immune response after vaccination compare between COVID-19 convalescents and naïve patients?
Conclusion
Patients with previous COVID-19 infection had higher levels of anti-spike IgG and avidity after vaccination compared to naïve patients, although both groups developed high-avidity antibodies.
Supporting Evidence
- High levels of anti-spike IgG were observed in both cohorts after vaccination.
- Patients with previous COVID-19 had significantly higher anti-spike IgG levels than naïve patients.
- Avidity index remained high in both cohorts, but did not change significantly over time in the COVID-19 cohort.
- Side effects were mild and of short duration, with no significant differences between cohorts.
Takeaway
This study shows that people who had COVID-19 before getting vaccinated have stronger immune responses than those who didn't, but both groups still get good protection from the vaccine.
Methodology
Blood samples were taken from COVID-19 convalescents and naïve patients at 1, 3, and 6 months after vaccination, and analyzed for anti-spike IgG and avidity using ELISA.
Potential Biases
The majority of participants were women, which may not represent the general population.
Limitations
The study included only younger patients with non-severe COVID-19 and lacked participants over 65 years old.
Participant Demographics
COVID-19 cohort: median age 51 years, 90% female; Naïve cohort: median age 51 years, 73% female.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website